IRulya Therapeutics Inc.: peers
IRulya Therapeutics Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
PureTech Health plc: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | IRulya Therapeutics Inc.base IRLA · 🇺🇸 US Percentile in Healthcare Percentile in USA | Cabaletta Bio, Inc. CABA · 🇺🇸 US Percentile in Healthcare Percentile in USA | Atea Pharmaceuticals, Inc. AVIR · 🇺🇸 US Percentile in Healthcare Percentile in USA | Kyverna Therapeutics, Inc. KYTX · 🇺🇸 US Percentile in Healthcare Percentile in USA | PureTech Health plc PRTC · 🇺🇸 US Percentile in Healthcare Percentile in USA | EyePoint Pharmaceuticals, Inc. EYPT · 🇺🇸 US Percentile in Healthcare Percentile in USA | Zura Bio Ltd ZURA · 🇺🇸 US Percentile in Healthcare Percentile in USA | Relmada Therapeutics, Inc. RLMD · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $343 MOct 30, 2026 · Market data5th of 8 | $343 MOct 30, 2026 · Market data3rd of 8 | $343 MOct 29, 2026 · Market data4th of 8 | $341 MOct 26, 2026 · Market data6th of 8 | $350 MAug 1, 2026 · Market data1st of 8 | $349 MOct 14, 2026 · Market data2nd of 8 | $340 MOct 23, 2026 · Market data7th of 8 | $337 MOct 20, 2026 · Market data8th of 8 | $343 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | —— | —— | $5 MFY2025 · ESEF2nd of 2 | $31 MFY2025 · SEC1st of 2 | —— | —— | $18 M2 ranked |
| Net income (Higher is better) | $-84 MFY2025 · SEC3rd of 8 | $-168 MFY2025 · SEC7th of 8 | $-158 MFY2025 · SEC5th of 8 | $-161 MFY2025 · SEC6th of 8 | $-110 MFY2025 · ESEF4th of 8 | $-232 MFY2025 · SEC8th of 8 | $-69 MFY2025 · SEC2nd of 8 | $-57 MFY2025 · SEC1st of 8 | $-134 M8 ranked |
| Employees (Better neither way: ranked highest first) | 55As on 2021 · Profile4th of 7 | 156December 31, 2025 · Profile1st of 7 | 19As on September 2020 · Profile6th of 7 | 130March 1, 2026 · Profile2nd of 7 | —— | 123As on 2021 · Profile3rd of 7 | 40December 31, 2025 · Profile5th of 7 | 10As on 2021 · Profile7th of 7 | 557 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | ———— | ———— | -3.5%FY2025 · ESEF1st of 219th20th | -27.5%FY2025 · SEC2nd of 29th4th | ———— | ———— | -15.5%2 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | ———— | ———— | -8.8%FY2025 · SEConly one with it13th11th | ———— | ———— | -8.8%— |
| Margins and returns | |||||||||
| Operating margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | -776.0%FY2025 · SEConly one with it2nd1st | ———— | ———— | -776.0%— |
| Net margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | -739.4%FY2025 · SEConly one with it2nd1st | ———— | ———— | -739.4%— |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | -775.9%FY2025 · SEConly one with it2nd1st | ———— | ———— | -775.9%— |
| Return on equity (Higher is better) | ———— | -127.0%FY2025 · SEC7th of 719th8th | -44.3%FY2025 · SEC2nd of 746th20th | -64.7%FY2025 · SEC4th of 736th15th | -30.8%FY2025 · ESEF1st of 753rd23rd | -72.2%FY2025 · SEC5th of 733rd14th | -55.3%FY2025 · SEC3rd of 741st17th | -94.1%FY2025 · SEC6th of 726th11th | -64.7%7 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 75.1׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 11.1×price Oct 14, 2026 · Market dataonly one with it75th90th | ———— | ———— | 11.1×— |
| Price to book (Better neither way: ranked highest first) | ———— | 3.1×price Oct 30, 2026 · Market data3rd of 650th63rd | 1.2×price Oct 29, 2026 · Market data5th of 624th28th | 1.5×price Oct 26, 2026 · Market data4th of 629th35th | 1.1׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 1.1×price Oct 14, 2026 · Market data6th of 621st25th | 3.4×price Oct 23, 2026 · Market data2nd of 654th65th | 3.9×price Oct 20, 2026 · Market data1st of 659th70th | 2.3×6 ranked |
| Free cash flow yield (Higher is better) | -12.2%price Oct 30, 2026 · Market data1st of 740th19th | -38.6%price Oct 30, 2026 · Market data4th of 722nd9th | -35.9%price Oct 29, 2026 · Market data3rd of 723rd10th | -45.1%price Oct 26, 2026 · Market data5th of 720th8th | -24.3%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -69.7%price Oct 14, 2026 · Market data7th of 713th5th | -19.1%price Oct 23, 2026 · Market data2nd of 733rd15th | -62.2%price Oct 20, 2026 · Market data6th of 715th6th | -38.6%7 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | 0.1×FY2025 · SEConly one with it21st15th | ———— | ———— | ———— | ———— | 0.1×— |
| Interest cover (Higher is better) | ———— | -86.1×FY2025 · SEConly one with it16th7th | ———— | ———— | ———— | ———— | ———— | ———— | -86.1×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 1 of 12FY2025 · Scorecard6th of 8 | 1 of 12FY2025 · Scorecard6th of 8 | 4 of 13FY2025 · Scorecard2nd of 8 | 4 of 12FY2025 · Scorecard1st of 8 | 0 of 5FY2025 · Scorecard8th of 8 | 2 of 20FY2025 · Scorecard4th of 8 | 1 of 10FY2025 · Scorecard4th of 8 | 2 of 12FY2025 · Scorecard3rd of 8 | 10% passed8 ranked |
| Valuation checks (Higher is better) | 0 of 4FY2025 · Scorecard4th of 7 | 0 of 4FY2025 · Scorecard4th of 7 | 1 of 4FY2025 · Scorecard1st of 7 | 1 of 4FY2025 · Scorecard1st of 7 | —— | 1 of 5FY2025 · Scorecard3rd of 7 | 0 of 4FY2025 · Scorecard4th of 7 | 0 of 4FY2025 · Scorecard4th of 7 | 0% passed7 ranked |
| Growth checks (Higher is better) | 0 of 2FY2025 · Scorecard2nd of 8 | 0 of 2FY2025 · Scorecard2nd of 8 | 0 of 2FY2025 · Scorecard2nd of 8 | 0 of 1FY2025 · Scorecard2nd of 8 | 0 of 2FY2025 · Scorecard2nd of 8 | 0 of 6FY2025 · Scorecard2nd of 8 | 0 of 1FY2025 · Scorecard2nd of 8 | 1 of 2FY2025 · Scorecard1st of 8 | 0% passed8 ranked |
| Profitability checks (Higher is better) | 0 of 2FY2025 · Scorecard1st of 8 | 0 of 3FY2025 · Scorecard1st of 8 | 0 of 3FY2025 · Scorecard1st of 8 | 0 of 2FY2025 · Scorecard1st of 8 | 0 of 2FY2025 · Scorecard1st of 8 | 0 of 5FY2025 · Scorecard1st of 8 | 0 of 2FY2025 · Scorecard1st of 8 | 0 of 3FY2025 · Scorecard1st of 8 | 0% passed8 ranked |
| Financial health checks (Higher is better) | 1 of 3FY2025 · Scorecard5th of 8 | 1 of 3FY2025 · Scorecard5th of 8 | 1 of 2FY2025 · Scorecard2nd of 8 | 3 of 4FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard8th of 8 | 1 of 3FY2025 · Scorecard5th of 8 | 1 of 2FY2025 · Scorecard2nd of 8 | 1 of 2FY2025 · Scorecard2nd of 8 | 42% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard2nd of 6 | —— | 2 of 2FY2025 · Scorecard1st of 6 | 0 of 1FY2025 · Scorecard2nd of 6 | —— | 0 of 1FY2025 · Scorecard2nd of 6 | 0 of 1FY2025 · Scorecard2nd of 6 | 0 of 1FY2025 · Scorecard2nd of 6 | 0% passed6 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 20.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 87.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 73.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 55.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | —— | 84.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 72.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 97.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 73.5%7 ranked |
| Institutions holding (Better neither way: ranked highest first) | 332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 1632026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 1272026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 1282026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | —— | 1902026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 1222026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 1352026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 1287 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | +17.5 pp2026-Q2 against 2026-Q1 · 13F1st of 6 | -1.3 pp2026-Q2 against 2026-Q1 · 13F6th of 6 | +3.2 pp2026-Q2 against 2026-Q1 · 13F4th of 6 | —— | +1.0 pp2026-Q2 against 2026-Q1 · 13F5th of 6 | +6.0 pp2026-Q2 against 2026-Q1 · 13F3rd of 6 | +13.6 pp2026-Q2 against 2026-Q1 · 13F2nd of 6 | +4.6 pp6 ranked |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | ———— | ———— | 7.4%FY2025 · SEConly one with it87th81st | ———— | ———— | ———— | ———— | ———— | 7.4%— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = IRulya Therapeutics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Cabaletta Bio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Atea Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Kyverna Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; PureTech Health plc: How market caps are worked out; EyePoint Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Zura Bio Ltd: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Relmada Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| IRulya Therapeutics Inc. | — | — | — |
| Cabaletta Bio, Inc. | — | — | — |
| Atea Pharmaceuticals, Inc. | — | — | — |
| Kyverna Therapeutics, Inc. | — | — | — |
| PureTech Health plc | — | — | — |
| EyePoint Pharmaceuticals, Inc. | -776.0%FY2025 | 2nd percentile in Healthcaremedian -7.7%, 674 companies | 1st percentile in USAmedian 3.5%, 2,594 companies |
| Zura Bio Ltd | — | — | — |
| Relmada Therapeutics, Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | IRulya Therapeutics Inc. | Cabaletta Bio, Inc. | Atea Pharmaceuticals, Inc. | Kyverna Therapeutics, Inc. | PureTech Health plc | EyePoint Pharmaceuticals, Inc. | Zura Bio Ltd | Relmada Therapeutics, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | — | $5 MESEF2nd | $31 MSEC1st | — | — |
| 2024 | — | — | — | — | $5 MESEF2nd | $43 MSEC1st | — | — |
| 2023 | — | — | — | — | $3 MESEF2nd | $46 MSEC1st | — | — |
| 2022 | — | — | — | — | — | $41 MSEC | — | — |
| 2021 | — | — | $351 MSEC1st | — | — | $37 MSEC2nd | — | — |
| 2020 | — | — | $49 MSEC1st | — | — | $34 MSEC2nd | — | — |
| 2019 | — | — | — | — | — | $20 MSEC | — | — |
| 2018 | — | — | — | — | — | $5 MSEC | — | — |
| 2017 | — | — | — | — | — | $8 MSEC | — | — |
| 2016 | — | — | — | — | — | $2 MSEC | — | — |
| 2015 | — | — | — | — | — | $27 MSEC | — | — |
| 2014 | — | — | — | — | — | $3 MSEC | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of IRulya Therapeutics Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Cabaletta Bio, Inc.CABA · 🇺🇸 USASame industry: Biotechnology · Similar size: $343 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $343 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Atea Pharmaceuticals, Inc.AVIR · 🇺🇸 USASame industry: Biotechnology · Similar size: $343 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $343 M (Oct 29, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Kyverna Therapeutics, Inc.KYTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $341 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $341 M (Oct 26, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- PureTech Health plcPRTC · 🇺🇸 USASame industry: Biotechnology · Similar size: $350 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $350 M (Aug 1, 2026) · revenue $5 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- EyePoint Pharmaceuticals, Inc.EYPT · 🇺🇸 USASame industry: Biotechnology · Similar size: $349 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $349 M (Oct 14, 2026) · revenue $31 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Zura Bio LtdZURA · 🇺🇸 USASame industry: Biotechnology · Similar size: $340 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $340 M (Oct 23, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Relmada Therapeutics, Inc.RLMD · 🇺🇸 USASame industry: Biotechnology · Similar size: $337 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $337 M (Oct 20, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Enanta Pharmaceuticals, Inc.ENTA · 🇺🇸 USASame industry: Biotechnology · Similar size: $334 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $334 M (Oct 16, 2026) · revenue $65 M (year to September 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- X4 Pharmaceuticals, Inc.XFOR · 🇺🇸 USASame industry: Biotechnology · Similar size: $332 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $332 M (Oct 28, 2026) · revenue $35 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Scribe Therapeutics Inc.SCTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $330 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $330 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Galectin Therapeutics Inc.GALT · 🇺🇸 USASame industry: Biotechnology · Similar size: $357 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $357 M (Oct 29, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Capricor Therapeutics, Inc.CAPR · 🇺🇸 USASame industry: Biotechnology · Similar size: $356 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $356 M (Oct 23, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.